744 related articles for article (PubMed ID: 17201732)
1. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease.
Hong X; Tang H; Wu L; Li L
J Pharm Pharmacol; 2006 Oct; 58(10):1391-8. PubMed ID: 17034663
[TBL] [Abstract][Full Text] [Related]
3. Preventive effects of total flavonoids of Litsea coreana leve on hepatic steatosis in rats fed with high fat diet.
Wang JQ; Li J; Zou YH; Cheng WM; Lu C; Zhang L; Ge JF; Huang C; Jin Y; Lv XW; Hu CM; Liu LP
J Ethnopharmacol; 2009 Jan; 121(1):54-60. PubMed ID: 18977425
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
5. [Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet].
Li Y; Huang B; Cheng H; Liang Z; Liu SY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):761-5. PubMed ID: 17260462
[TBL] [Abstract][Full Text] [Related]
6. [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].
Bai XP; Li HL; Yang WY; Xiao JZ; Wang B; Du RQ; Lou DJ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):268-70. PubMed ID: 18361841
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
8. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
9. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.
Yalniz M; Bahcecioglu IH; Kuzu N; Poyrazoglu OK; Bulmus O; Celebi S; Ustundag B; Ozercan IH; Sahin K
J Gastroenterol Hepatol; 2007 Nov; 22(11):2009-14. PubMed ID: 17914984
[TBL] [Abstract][Full Text] [Related]
10. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats.
Cui WX; Yang J; Chen XQ; Mao Q; Wei XL; Wen XD; Wang Q
Am J Chin Med; 2013; 41(3):487-502. PubMed ID: 23711137
[TBL] [Abstract][Full Text] [Related]
11. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
13. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease.
Duan XY; Zhao HP; Fan JG
J Dig Dis; 2010 Apr; 11(2):94-100. PubMed ID: 20402835
[TBL] [Abstract][Full Text] [Related]
14. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].
Yan M; Meng FL; Lu RJ; Jia XQ; Zhao XC
Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401
[TBL] [Abstract][Full Text] [Related]
15. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
16. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect?
Safwat GM; Pisanò S; D'Amore E; Borioni G; Napolitano M; Kamal AA; Ballanti P; Botham KM; Bravo E
Nutrition; 2009; 25(11-12):1157-68. PubMed ID: 19592219
[TBL] [Abstract][Full Text] [Related]
17. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
18. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet.
Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
20. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice.
Pinto Lde F; Compri CM; Fornari JV; Bartchewsky W; Cintra DE; Trevisan M; Carvalho Pde O; Ribeiro ML; Velloso LA; Saad MJ; Pedrazzoli J; Gambero A
Liver Int; 2010 Apr; 30(4):603-10. PubMed ID: 20088867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
